admin

Earlier this year, both Apple and Google presented competing visions for how we’ll use apps and wearables to gather data about our bodies and share it via our phones. Apple called its software HealthKit, while Google presented Google Fit.

If things had gone according to plan on Wednesday, Apple would be enjoying a head start over Google, with HealthKit released along with iOS 8, its new mobile software for iPhones and iPads. (Google Fit is still unreleased beyond a “developer preview.”) 

The 2014 Innovation2Commercialization Conference will be held on October 23rd at the Universities at Shady Grove in Rockville. This is our third year and we would like to ask you participate again to support and encourage the innovators, scientists, technologists and entrepreneurs in our area.

The conference will be held from 7:30am-3:30pm, with three panels: Innovation, Commercialization and Financing, and a special Keynote Speaker – Rachel King, CEO, GlycoMimetics. The program will spotlight serial entrepreneurs and successful tech transfer to product from the Naval Research Laboratory and The Johns Hopkins University – including a full panel discussion on the successful development to exit for Amplimmune.

As Partners in the past, we hope you found participation in the I2C Conference productive and plan to join us again this year.

DC I-Corps, a new, NSF-supported program designed to foster, grow and nurture an innovation ecosystem in the Mid-Atlantic Region, is now accepting applications for its fall cohort, beginning on October 9. Applications will be accepted on a rolling basis up until that date. Apply here.

Open to research teams and technology entrepreneurs from universities, federal laboratories, agencies and the general community, the free program guides researchers in exploring the commercial potential of their inventions.

Since its passage more than two years ago, the Jumpstart Our Business Startups (JOBS) Act, which was designed to decrease regulatory burdens for raising capital, has spurred more than 110 IPOs among biotechnology companies alone. These are companies working to find cures for cancer, cardiovascular disease, blood disorders, and infectious diseases, among other conditions. The Securities and Exchange Commission (SEC) is now in the process of finalizing another important provision of the law that could further encourage biotech capital formation and investment.

Some of the trends in American health care are obvious: Managing costs in the age of Obamacare, patients using online information to take charge of their own health and wellness, and finding ways to deliver care in settings other than hospitals and clinics. 

Those trends become specific, sometimes knotty, challenges for people engaged in building the tools needed to effectively, efficiently and safely deliver health care.

Envisioning, designing and manufacturing medical devices – which range from robots to sensors, and from surgical instruments to software that allows devices to communicate with one another – was the topic of a conference Thursday and Friday in Chicago. 

This editor attended TEDMED 2014 in DC and had a chance to speak with some of the innovative start ups in the Hive, a showcase of new medical technologies.

BeneVir has developed an impressive immunotherapy for cancer that has the potential to become a lasting, durable cure to the disease. While other existing immunotherapy treatments exist, these solutions only help the immune system scour the body for known cancer cells afflicting a patient. These solutions fail to educate the immune system on how to predict, recognize, and kill cancer mutations that avoid the immune system and lead to a recurrence of the disease. BeneVir’s solution uses a natural human virus whose genes have been altered to allow the virus to target both the original cancer cells and their mutations. Prior to becoming a company, BeneVir’s founders originally developed their immunotherapy concept and licensed the solution to T-Vec, which was acquired by Amgen for $1B in 2011. This original concept recently completed a Phase 3 clinical trial showing a 16% durable cure for melanoma. With this success, BeneVir was formed to expand on the original innovation with what the founder calls version 2.0 plus. With deep technical knowledge, BeneVir is refining their original immunotherapy solution to become an even more potent cancer therapy.

Dutch venture capitalist Aglaia has announced the launch of Aglaia Oncology Fund II. Investors contribute a total of $65 million to the fund, whose target size is $80 to $100 million. Like its predecessor Aglaia Oncology Fund I, the fund is backed by high-net-worth families. The group of investors has now been expanded to include several institutional investors, including the European Investment Fund (EIF), which has made a substantial commitment. Aglaia is also one of the funds selected under the Dutch Venture Initiative, an investment fund recently launched by the Netherlands Ministry of Economic Affairs.

Through the new fund, Aglaia will be investing in an estimated ten to fifteen biotechnology start-ups which are in the process of developing groundbreaking technologies aimed at preventing and curing cancer.

AstraZeneca and Eli Lilly and Company have reached an agreement for the development and commercialization of the oral beta secretes cleaving enzyme (BACE) inhibitor, AZD3293, which might become a viable treatment for Alzheimer’s disease. The oral therapy is expected to prevent the formation of amyloid plaque, which is comprised of peptides called amyloid beta, and slow the disease progression.

The agreement established stipulates that AstraZeneca will pay up to $500 million in development and regulatory milestone payments. Lilly announced that it is planning on receiving the first milestone payment of $50 million in the first half of 2015. Future costs will be equally shared by both companies, including net global revenues post-launch.

The intersection of health and big data is getting more crowded. San Mateo, Calif.-based Lumiata is the latest company to get venture backing for technology that crunches data with the aim of improving medical care, Yuliya Chernova reports for Dow Jones VentureWire.

The company has already run an analysis of some 100,000 BlueCross BlueShield patients that found about 10,000 people who were very likely to have congestive heart failure, even though they were undiagnosed. Now the insurance provider, which is also an investor in the company, is alerting doctors who have those patients about this potential missed diagnosis.